Quizartinib

Overview

Quizartinib (AC220) is an orally active, potent and selective FLT3 inhibitor. Quizartinib inhibits kinase activity of mutant-FLT3, - PDGFRA and - KIT isoforms and inhibits autophosphorylation. Quizartinib inhibits cellular proliferation, induces apoptosis in cancer cells. Quizartinib can be used for the research of cancer .

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > PDGFR | Products > Signaling Pathways > c-Kit

Product Information

• Catalog No.: HY-13001
• CAS No.: 950769-58-1
• Molecular Formula: C29H32N6O4S
• Molecular Weight: 560.67
• Purity: 99.08%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 1 mg/mL (1.78 mM); Clear solution
• Availability: In-stock

Source

Original product source